Meta Platforms Inc vs ResMed Inc. — how do they compare? Meta Platforms Inc trades at $640.94 (market cap $1.64T), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: Meta Platforms Inc is far larger — about 56.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| META | RMD | |
|---|---|---|
Market Cap | $1.64T | $28.81B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $293.73 |
52-Week Low | $525.72 | $182.82 |
Enterprise Value | $1.65T | $27.99B |
Dividend Yield | 0.33% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $643.81, down 0.34% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income of $60.5B, and impressive profitability margins including 81.9% gross margin and 32.8% net margin. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70.
The outlook remains positive with analyst consensus price target of $817.32 representing 27% upside potential. Key opportunities include AI monetization through Muse Spark and strong advertising revenue growth, while risks involve ongoing litigation regarding youth addiction claims and elevated capital expenditures for AI infrastructure. Wall Street maintains strong bullish sentiment with 79% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →